Abstract
Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.
Publication types
-
Practice Guideline
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aftercare / standards
-
Antineoplastic Agents, Immunological / standards
-
Antineoplastic Agents, Immunological / therapeutic use
-
Drug Resistance, Neoplasm
-
Humans
-
Immunotherapy, Adoptive / methods
-
Immunotherapy, Adoptive / standards
-
Lymphoma, Follicular / immunology
-
Lymphoma, Follicular / mortality
-
Lymphoma, Follicular / pathology
-
Lymphoma, Follicular / therapy*
-
Lymphoma, Large B-Cell, Diffuse / immunology
-
Lymphoma, Large B-Cell, Diffuse / mortality
-
Lymphoma, Large B-Cell, Diffuse / pathology
-
Lymphoma, Large B-Cell, Diffuse / therapy*
-
Medical Oncology / methods
-
Medical Oncology / standards*
-
Neoplasm Recurrence, Local / immunology
-
Neoplasm Recurrence, Local / mortality
-
Neoplasm Recurrence, Local / pathology
-
Neoplasm Recurrence, Local / therapy*
-
Neoplasm Staging
-
Phosphoinositide-3 Kinase Inhibitors / standards
-
Phosphoinositide-3 Kinase Inhibitors / therapeutic use
-
Receptors, Chimeric Antigen / immunology
-
Signal Transduction / drug effects
-
Signal Transduction / immunology
-
United States
Substances
-
Antineoplastic Agents, Immunological
-
Phosphoinositide-3 Kinase Inhibitors
-
Receptors, Chimeric Antigen